The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them.
1. A method for treating cognitive impairment in a patient suffering from Alzheimer's disease or schizophrenia comprising administering to the subject a compound of the formula:
in a pharmaceutically effective amount,
in which
R 1 is a group of the formula —NR 2 —CO—NR 3 R 4 , —NR 2 —CO—CO—OR 5 , —NH—SO 2 R 6 , —SO 2 NHR 7 or —NH—CO—R 8 , where
R 2 is hydrogen or C 1 -C 6 -alkyl,
R 3 and R 4 are independently of one another hydrogen, C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl or phenyl, which is optionally substituted by up to 3 radicals independently of one another selected from the group of halogen, cyano, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, trifluoromethyl and trifluoromethoxy, or
R 3 and R 4 together with the nitrogen atom to which they are bonded form a 5- to 6-membered heterocyclyl,
R 5 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl or aryl, where C 1 -C 6 -alkyl is optionally substituted by aryl,
R 6 is C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5- to 6-membered heteroaryl, where C 1 -C 6 -alkyl is optionally substituted by aryl,
R 7 is hydrogen, C 1 -C 6 -alkyl, C 3 -C 8 -cycloalkyl, 5- to 6-membered heterocyclyl, aryl or 5- to 6-membered heteroaryl, where C 1 -C 6 -alkyl is optionally substituted by aryl,
R 8 is C 3 -C 8 -cycloalkyl, C 1 -C 6 -alkyl or phenyl, where C 1 -C 6 -alkyl is substituted by C 1 -C 6 -alkoxy and phenyl by 1 to 3 radicals independently of one another selected from the group of halogen, cyano, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, trifluoromethyl and trifluoromethoxy, or a salt thereof.
2. The method of claim 1 , wherein the cognitive impairment is Alzheimer's disease.
3. The method of claim 1 wherein the cognitive impairment is schizophrenia.
4. The method of claim 1 , further comprising co-administering a second active ingredient for the treatment of the cognitive impairment.
5. The method of claim 1 , wherein the administering is by an oral, transdermal, parenteral or inhalation route.